ArticleBritish journal of cancer2016
Adjuvant ovarian function suppression and cognitive function in women with breast cancer.
Article in British journal of cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00659373 (Investigating Cognitive Function for Patients Participating in the SOFT Trial in Selected Centers), which is not on this map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Investigating Cognitive Function for Patients Participating in the SOFT Trial in Selected Centers
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Ovarian suppression for adjuvant treatment of hormone receptor-positive early breast cancer.The Cochrane database of systematic reviews · 2020Pooled it
- Trial
- Long-term health-related quality of life among adolescent and young adult breast cancer survivors.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2025Article
- Ovarian Suppression: Early Menopause, Late Effects.Current oncology reports · 2024Review
- Ovarian Suppression: Early Menopause and Late Effects.Current treatment options in oncology · 2024Review
- Feasibility of Cognitive Training to Promote Recovery in Cancer-Related Cognitive Impairment in Adolescent and Young Adult Patients.Journal of adolescent and young adult oncology · 2022Article
- Long-Term Cognitive Dysfunction in Cancer Survivors.Frontiers in molecular biosciences · 2021Review
- Cancer-related cognitive impairment: an update on state of the art, detection, and management strategies in cancer survivors.Annals of oncology : official journal of the European Society for Medical Oncology · 2019Review
- Long-term comparisons of the efficacy, safety, and pregnancy outcomes of adjuvant tamoxifen plus ovarian function suppression in premenopausal Han and Zhuang Chinese patients with hormone receptor-positive early breast cancer.The Journal of international medical research · 2019Article
- An Italian Delphi study to evaluate consensus on adjuvant endocrine therapy in premenopausal patients with breast cancer: the ERA project.BMC cancer · 2018Article
- Should age impact breast cancer management in young women? Fine tuning of treatment guidelines.Therapeutic advances in medical oncology · 2018Review
- Triptorelin: A Review of its Use as an Adjuvant Anticancer Therapy in Early Breast Cancer.Drugs · 2017Review
- Ovarian Aging in Women With BRCA Germline Mutations.The Journal of clinical endocrinology and metabolism · 2017Article
- Systemic therapies and cognitive impairment for breast cancer: an overview of the current literature.Medical oncology (Northwood, London, England) · 2017Review
- Ovarian Function Suppression in Premenopausal Women with Early-Stage Breast Cancer.Current treatment options in oncology · 2017Review
- Reply to F. Tomao et al.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2016Article
- Understanding the impact of breast cancer adjuvant endocrine therapy on cognitive function: a work in progress.British journal of cancer · 2016Article
- Cognitive Functioning and Psychological Well-being in Breast Cancer Patients on Endocrine Therapy.In vivo (Athens, Greece)Article
Corrections and comments
- Commented on by
Authors and funding
22 authors at 11 institutions in 4 countries.
Funding
Abstract
backgroundTo examine the effect on cognitive function of adjuvant ovarian function suppression (OFS) for breast cancer.
methodsThe Suppression of Ovarian Function (SOFT) trial randomised premenopausal women with hormone receptor-positive breast cancer to 5 years adjuvant endocrine therapy with tamoxifen+OFS, exemestane+OFS or tamoxifen alone. The Co-SOFT substudy assessed objective cognitive function and patient reported outcomes at randomisation (T0), and 1 year later (T1); the primary endpoint was change in global cognitive function, measured by the composite objective cognitive function score. Data were compared for the pooled tamoxifen+OFS and exemestane+OFS groups vs the tamoxifen alone group using the Wilcoxon rank-sum test.
resultsOf 86 participants, 74 underwent both T0 and T1 cognitive testing; 54 randomised to OFS+ either tamoxifen (28) or exemestane (26) and 20 randomised to tamoxifen alone. There was no significant difference in the changes in the composite cognitive function scores between the OFS+ tamoxifen or exemestane groups and the tamoxifen group (mean±s.d., -0.21±0.92 vs -0.04±0.49, respectively, P=0.71, effect size=-0.20), regardless of prior chemotherapy status, and adjusting for baseline characteristics.
conclusionsThe Co-SOFT study, although limited by small samples size, provides no evidence that adding OFS to adjuvant oral endocrine therapy substantially affects global cognitive function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.